Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- What are NK (Natural killer) cell biological characteristics?
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- Can drinking red wine soften blood vessels?
- The new era of nanomedicine+mRNA is coming
- Moderna cooperates to develop non-viral gene therapy
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Sanofi oral SERD failed: Only one ADC in the phase 3 tumor pipeline.
On August 17, Sanofi announced that it will discontinue the global clinical development program for its investigational oral selective estrogen receptor degrader (SERD) amcenestrant.
The decision was based on the results of a pre-specified interim analysis of the Phase 3 AMERA-5 trial in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer , comparing the efficacy of amcenestrant combined with palbociclib and letrozole combined with palbociclib.
The Independent Data Monitoring Committee (IDMC) found that the combination of amcenestrant and palbociclib did not meet the predetermined limit for continued use compared with the control group and recommended that the trial be discontinued.
Sanofi said all other studies on amcenestrant, including early-stage breast cancer (AMEERA-6), will be discontinued.
Previously, Sanofi had seen the program as a future “endocrine backbone therapy” for breast cancer.
Amcenestrant took a major hit in March, when Sanofi disclosed the failure of an often-delayed phase 2 trial investigating the drug as a monotherapy for ER-positive, HER2-negative breast cancer.
(source:internet, reference only)
Disclaimer of medicaltrend.org
